Why the study?
Does Adeno-associated virus-mediated NFYA overexpression and SGLT2 inhibition ameliorate exercise-induced pulmonary hypertension in preclinical models of HFpEF and CpcPH?
Does Adeno-associated virus-mediated NFYA overexpression and SGLT2 inhibition ameliorate exercise-induced pulmonary hypertension in preclinical models of HFpEF and CpcPH?
Answers are grounded in this paper and cite their sources.
In preclinical models of HFpEF and CpcPH, metabolic syndrome-driven pulmonary vascular dysfunction is mediated by ROS-miR-193b-NFYA signaling, which can be ameliorated by NFYA overexpression or SGLT2 inhibition.
In heart failure with preserved ejection fraction and CpcPH models, metabolic syndrome contributes to pulmonary vascular dysfunction and EIPH through enhanced reactive oxygen species and miR-193b expression, which downregulates NFYA-dependent sGCβ1 expression. Adeno-associated virus-mediated NFYA overexpression and SGLT2 inhibition restore NFYA-sGCβ1-cGMP signaling and ameliorate EIPH.
No takes yet. Share an insight, caveat, or question.
Satoh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: